• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Upcoming EU referendum delays UK pharma market changes

Upcoming EU referendum delays UK pharma market changes

April 18, 2016
CenterWatch Staff

Civil servants must observe a period of “purdah” in the weeks before a general election or referendum, which restricts government activity to avoid unfairly influencing public opinion. This has hit two major consultations for the pharma industry—the Accelerated Access Review (AAR) and proposed changes to the medicines pricing system known as the Statutory Scheme. The AAR is the brainchild of life sciences minister George Freeman, who wants it to re-shape the U.K. market and the National Health Service (NHS) around encouraging medical innovation, and remove some of the blocks and bottlenecks which plague the current system.

It released its interim report in October 2015, setting out five propositions to speed up access to transformative health technology that can change the lives of NHS patients.

This isn't the first time the report has been delayed—the final AAR report was originally scheduled for autumn 2015, then pushed on to spring 2016. Civil servants now say the final report will be launched shortly after referendum day 23 June, and have told pharma that it remains a “key priority.”

However, there remains skepticism about the AAR's ability to have a big impact on the U.K. sector and NHS uptake of new medicines, medical devices and other new technology—mainly because of the unprecedented squeeze on NHS spending.

Also, the AAR isn't able to recommend changes to the core working of NHS cost effectiveness watchdog NICE, or the main medicines pricing system, the pharmaceutical price regulation scheme (PPRS). This means the report can't be truly comprehensive, particularly as the pharma industry wants to see fundamental reform to how NICE works.

Despite these delays, industry body the ABPI remains upbeat. A spokesperson for the organization said, "We still believe that the review is a great and unique opportunity to enable greater patient access and benefit from new medicines, despite the delay in publication."

Top of the ABPI's wish list is for the U.K. to adopt new medicines more quickly, as it still lags behind European neighbors in this respect.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing